Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | GPR4 | P46093 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8273728 | 0.91 | PARP15 (0.51) | PARP15PARP10PARP2TDP1RORC | |
| SCHEMBL14864495 | 0.85 | HRH3 (0.51) | PARP15PARP10PARP2TDP1RORC | |
| SCHEMBL11941581 | 0.84 | PARP15 (0.54) | PARP15PARP10PARP2TDP1RORC | |
| SCHEMBL9970995 | 0.84 | PARP15 (0.54) | PARP15PARP10PARP2TDP1RORC | |
| SCHEMBL14508997 | 0.83 | PARP15 (0.55) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL20766456 | 0.80 | PARP15 (0.56) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL9813516 | 0.80 | ACACB (0.53) | PARP15PARP10PARP2TDP1RORC | |
| SCHEMBL8285615 | 0.79 | PARP15 (0.51) | PARP15PARP10PARP2 | |
| SCHEMBL8284686 | 0.79 | PARP15 (0.50) | PARP15PARP10PARP2TDP1 | |
| SCHEMBL14451432 | 0.79 | PARP15 (0.50) | PARP15PARP10PARP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | PARP15 1537/4885PARP10 1137/4885PARP2 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.